<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The survival rate of children and adolescents suffering <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been significantly improved within the last decades </plain></SENT>
<SENT sid="1" pm="."><plain>This has been achieved by a continuously intensified therapy and progress in supportive care to prevent and treat complications </plain></SENT>
<SENT sid="2" pm="."><plain>In Germany, the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-BFM trials 98 (n=413) and 2004 (n=499) enrolled 912 children and adolescents as protocol patients (1998-2010) </plain></SENT>
<SENT sid="3" pm="."><plain>The 5-year-overall survival was 71±2% </plain></SENT>
<SENT sid="4" pm="."><plain>In the previous studies prognosis and subsequent treatment stratification based on <z:mp ids='MP_0000002'>morphology</z:mp>, cytochemistry and white blood cell count </plain></SENT>
<SENT sid="5" pm="."><plain>Today, the identification of new genetic aberrations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> enables a genetically determined estimation of prognosis, although treatment response must be considered for treatment stratification </plain></SENT>
<SENT sid="6" pm="."><plain>The group with a favorable prognosis summarized <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with t(8;21), inv(16), t(15;17), t(1;11), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype and NPM1-mutation (n=253; EFS 74±3%, OS 88±2%) </plain></SENT>
<SENT sid="7" pm="."><plain>A poor prognosis (HR-group) must be expected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with t(4;11), t(5;11), t(6;11), t(6;9), t(7;12), t(9;22), <z:mp ids='MP_0004026'>Monosomy</z:mp> 7, combined FLT3/WT1-mutation, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with der(12p)-aberration (n=101; EFS 30±5%; OS 56±5%) </plain></SENT>
<SENT sid="8" pm="."><plain>The intermediate group summarizes <z:hpo ids='HP_0000001'>all</z:hpo> other subgroups especially <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotyp, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with FLT3-ITD or t(9;11) (n=558; EFS 43±2%; OS 64±2%) </plain></SENT>
<SENT sid="9" pm="."><plain>The validation of the internationally identified, genetically determined prognostic factors within the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-BFM (Germany) study population will support treatment recommendations </plain></SENT>
</text></document>